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physiological methods and validated questionnaires. Ten 
single nucleotide polymorphisms (SNPs) have previously been 
suggested to be predictive of late radiation induced toxicity 
by GWAS studies or candidate gene studies. The objective of 
this study was to test the ten SNPs in this unique cohort. The 
strength of the reportings as well as the clinical data 
available served as the rationale for using our rather small 
cohort as a validation cohort. 
Materials and Methods: The patients in this cohort have 
received EBRT 70-78 Gy for prostate cancer with curative 
intent. Functional toxicity endpoints have been examined by 
sigmoidoscopy, manometry, endoanal ultrasonography and 
impedance planimetry in an earlier study. Objective 
endpoints include the Vienna Rectoscopy Score (VRS), cross 
sectional area (CSA) of rectum at distension, maximum 
resting pressure (MRP) and maximum squeezing pressure 
(MSP) of anal sphincters. The subjective measure RT-
Anorectal dysfunction score (RT-ARD) was obtained from the 
questionnaires. Biological material from the patients in this 
cohort is available from an established research biobank. The 
SNPs were investigated in DNA from fibroblasts with TaqMan 
SNP assays. Statistical analyses was carried out with Stata13. 
For each SNP (table I) the reported risk allele was identified 
and due to the small sample size a risk-allele average was 
created for each patient. This risk-allele average was 
correlated to RT-ARD, VRS, MRP, MSP and CSA by Spearman's 
rank correlation. 
 
Results: All SNPs in the cohort were in Hardy-Weinberg 
equilibrium. Preliminary results showed no statistically 
significant correlations between the risk-allele average and 
toxicity end points tested. Spearman´s rank correlations ρ 
(rho) were as follows: VRS ρ = 0.17 p = 0.33, MRP ρ = -0.08 p 
= 0.64, MSP ρ = 0.02 p = 0.91, CSA ρ = 0.03 p = 0.88, RT-ARD 
ρ = -0.26 p = 0.13. 
Conclusions: Preliminary results indicate no correlation 
between risk-allele average and late radiation toxicity end 
points tested. The cohort will be expanded with 234 patients 
having received the same treatment and with the same 
questionnaire data on morbidity.  
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Purpose/Objective: Radiation-induced lung toxicity (RILT) 
varies significantly between patients at similar doses to the 
lung and can seriously affect the quality of life. The 
identification of prognostic biomarkers for radiation-induced 
toxicity is crucial for personalized RT: to select patients for 
proton therapy or dose escalation. We hypothesized variation 
in the mitochondrial genome (mtDNA) is a biomarker for 
RILT, since mitochondria and RT have several processes in 
common, among which reactive oxygen species (ROS) 
production. 
Materials and Methods: Blood DNA was isolated from 372 
(training set, Maastricht) and 68 (test set, Ghent) lung cancer 
patients. After exclusion of patients that had surgery, had 
other tumors within 5 years prior to lung cancer, received a 
palliative dose or for which baseline dyspnea score was 
unknown, 277 and 53 patients were remaining for the training 
and test set respectively. Baseline dyspnea (at the start of 
RT) and maximal dyspnea 3-6 months after RT were scored 
according to the CTCAE version 3.0 criteria. The endpoint of 
analysis was dyspnea grade>=2 after RT. Additionally, DNA 
was obtained from fibroblasts of 21 breast cancer patients for 
which the toxicity grade after radiotherapy was known 
(LENT/SOMA criteria). mtDNA was resequenced using 
mitochips and homoplasmic deviations from the revised 
Cambridge reference sequence were recorded. Variants were 
classified into 7 functional categories based on their 
theoretical effect on OXPHOS function. 
Results: Using the 7 functional categories as input features, 
logistic regression analysis corrected for baseline dyspnea 
score resulted in an AUC of 0.78 for the training set, which 
was significantly better than the current international gold 
standard Mean Lung Dose (AUC 0.57; p < 0.001). The AUC for 
the test set was 0.66 but the power of the validation was 
limited due to the small sample size. Validation in a second 
external test set is ongoing. Additionally, using mtDNA 
variation data we were able to classify breast cancer patients 
in the correct toxicity group with 80% accuracy. 
Conclusions: Our data showed that mtDNA variation is a 
valuable biomarker for RILT. Furthermore, we have 
preliminary data in breast cancer patients that the predictive 
effect of mtDNA might be applicable to radiation toxicity in 
general. 
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Purpose/Objective: (1) To quantify the geometric and 
dosimetric variability of prostate contouring on US for low-
dose-rate brachytherapy. (2) To assess the dosimetric 
variability of registrations of T1-weighted MRI with C-arm 
cone beam CT (CBCT) and the currently performed US-CBCT 
registrations. 
Materials and Methods: VariSeed studies of eleven patients 
previously treated with low-dose-rate brachytherapy at our 
institute were enrolled in a multi-observer study. Six 
observers performed three sessions of prostate contouring on 
US and registrations of US- and MRI-CBCT. 
Prostate contours were sampled at 10 degree increments of 
the polar and azimuthal angles from the center of mass. The 
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radial distances were compared to those of the clinically 
used contours (inter-observer) and the average contours per 
patient and observer (intra-observer). The registration 
process was initiated with the localization of gold fiducial 
markers (FMs) and, if necessary, adjusted manually for 
rotation and/or translation. Prostate V100 and D90 were 
determined for each contour and registration. The two 
dosimetric parameters (DPs) were scaled with the patients 
clinical DPs (inter, see Figure 1) or the patients average per 
observer (intra) to remove the natural variation in DPs 
between patients. 
Results: Prostate contours on US resulted in an inter-observer 
variability of 1.1 mm (1 SD with respect to the clinical 
contours) and an intra-observer variability of 0.6 mm (1 SD 
with respect to the average contour per patient and 
observer). US-contouring alone led to dosimetric differences 
of 1.6% of the clinical V100 and 9.3% of the clinical D90, and 
an intra-observer variability of 0.6% (V100) and 1.0% (D90). 
US-CBCT registrations varied within 2.0% of the clinical V100 
and 3.1% of the clinical D90. For MRI-CBCT registration, this 
was 1.3% and 2.1% respectively. The intra-observer 
variabilities of US-CBCT (V100: 0.9% and D90: 1.5%) and MRI-
CBCT (V100: 0.7% and D90: 1.0%) registration were smaller 
than the inter-observer variabilities. During registration, 
observers found 91% of the FMs on US, 100% on CBCT and 99% 
on MRI. 78% of the US-CBCT registrations were manually 
adjusted based on the urethra contours and iodine seeds. 




Conclusions: US- and MRI-CBCT registrations showed little 
variability compared to the inter-observer variability in US-
contouring. Inter-observer contouring caused D90 variations 
of 9.3% from the clinical value. The intra-observer contouring 
variability was comparable to the registration variability. 
Good FM visibility on MRI scans resulted in small registration 
variabilities. The inferior FM visibility on US was compensated 
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Purpose/Objective: Evaluation of tolerance, early and late 
toxicity of HDR brachytherapy combined with interstitial 
hyperthermia (IHT) in patients treated for prostate cancer. 
Materials and Methods: 105 patients were treated for 
prostate cancer using HDRBT combined with IHT. 79 patients 
were treated fo primary prostate adenocarcinoma, and 26 
patients for local recurrence after previous definitive EBRT. 
The treatment of 76 patients consisted of external beam 
radiotherapy (EBRT) to the total dose of 50 Gy and HDRBT 
boost (21Gy in 2 fractions), 3 patients received HDRBT as a 
monotherapy to the total dose of 45 Gy in 3 fractions. 
Salvage HDRBT for local cancer recurrence was performed to 
the total dose of 30 Gy in 3 fractions. IHT was planned before 
each HDRBT fraction to the temperature of 40-43ºC for 60 
minutes. Toxicity was assessed according to Common Toxicity 
Criteria for Adverse Events version 4.03. 
Results: The median follow-up time was 26.4 months (range 
7 – 61 months). We didn't observe any grade 3 or higher 
gastrointestinal (GI) or genitourinary (GU) early toxicities. 
Early GU grade 1 and 2 toxicities were common, but only two 
patients (1,9%) experienced acute urethral stenosis and 
required temporary catheterisation (grade 2). Only two 
patients (1,9%) developed late grade 3 urinary tract 
obstruction with urinary retention, which required 
transurethral resection of the prostate (TURP). The incidence 
of grade 2 toxicity in this group of patients did not exceed 
30%. There were no late grade 2 or higher complications from 
the gastrointestinal tract. There were no statistically 
significant differences in early complications between the 
groups of patients treated with radical and salvage intent, 
except for haematuria (p <0.01) and rectal bleeding (p 
<0.01). 
Conclusions:The combination of HDRBT with IHT is well 
tolerated. The profile of early and late complications is 
acceptable, while the incidence of grade 3 toxicity remained 
within a few percent only. 
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Purpose/Objective: High Dose-Rate brachytherapy (HDRB) 
for the treatment of prostate cancer provides biochemical 
control comparable to other treatment modalities with the 
benefit of reducing dose to the OARs. Generally delivered in 
conjunction with external beam radiotherapy HDRB has the 
potential advantage of allowing dose escalation due to the 
high dose delivered during the treatment fraction. However, 
the wide ranges of fractionation regimes used in different 
centres make it difficult to establish clear guidelines for 
